MedPath

Post-Market Study of the Ellipse PRECICE Intramedullary Limb Lengthening System

Not Applicable
Conditions
Limb Length Discrepancy
Interventions
Device: PRECICE System
Registration Number
NCT01601301
Lead Sponsor
Ellipse Technologies, Inc.
Brief Summary

The purpose of this study is to obtain post market performance and safety data of the Ellipse PRECICE Intramedullary Limb Lengthening System for subjects undergoing unilateral limb lengthening.

Detailed Description

Subject data will be reviewed at the following visits:

* Preoperative

* Operative

* Every 7 to 14 days through Distraction Phase

* Every 4 to 6 weeks through Consolidation Phase

* 6-Month Post-Consolidation

* 12-Month Post-Consolidation

* 18-Month Post-Consolidation

* 24-Month Post-Consolidation

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
32
Inclusion Criteria
  • Leg length discrepancy ≥ 1.5 cm and ≤ 6.5 cm due to short femur or tibia
  • Weight ≤ 114 kg if implanted with the 10.7 mm or 12.5 mm diameter nail, or ≤ 57 kg if implanted with the 8.5 mm diameter nail
  • Skeletally mature
  • Intramedullary canal without offset
  • Tibia or femur sufficient to contain the implant
  • Availability, willingness, and sufficient cognitive awareness to comply with protocol procedures and schedule
  • Must sign informed consent to permit the use of personal health data
Exclusion Criteria
  • Active infection or previous history of deep infection in the involved bone
  • Metal allergies or sensitivities to the components of the device
  • Distance from the nearest convenient external surface of the treated limb to the intramedullary canal > 38 mm for the 8.5 mm PRECICE nail, > 51 mm for the 10.7 mm PRECICE nail, or > 76 mm for the 12.5 mm PRECICE nail
  • Significant range of motion deficit of the adjacent joints
  • Patients with a pacemaker, implanted cardiac defibrillator, or any other electronic or magnetic implant
  • Patients who require an MRI during implantation
  • Non-union
  • Impassable or obstructed intramedullary canal
  • Significant angular deformity that prevents device placement
  • Cannot bear weight on the contralateral limb
  • Procedural osteotomy cannot be made in an appropriate location
  • Deformities that require multilevel osteotomies or bi-lateral implantation at the time of study index surgery
  • Systemic bone disease
  • Pregnant or nursing women
  • Inadequate vascularity or evidence of vascular disease or peripheral neuropathy
  • Malignancies or tumors in the involved bone
  • Patient is a drug abuser
  • Open wounds or ulcers that could compromise treatment

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
PRECICE SystemPRECICE System-
Primary Outcome Measures
NameTimeMethod
Distraction Control: actual distraction rate vs. target distraction ratePostoperatively, every 7-10 days up until the subject's distraction regimen is complete, an expected average of 33 days
Secondary Outcome Measures
NameTimeMethod
Number of days to complete lengtheningPostoperatively, every 7-10 days up until the subject's distraction regimen is complete, an expected average of 33 days
Adverse EventsUp to 24 months post-consolidation of the treated limb, an expected total average of 29 months
Procedure-related complicationsUp to 24 months post-consolidation of the treated limb, an expected total average of 29 months
Number of days to complete full weight bearingUp to an expected average of 99 days.
Number of days to full consolidationFollowing completion of the subject's distraction regimen, every 4-6 weeks until the subject's treated limb is evaluated as consolidated, an expected average of 66 days
Bone UnionFollowing completion of the subject's distraction regimen, every 4-6 weeks until the subject's treated limb is evaluated as consolidated, an expected average of 66 days
PainUp to 24 months post-consolidation of the treated limb, an expected total average of 29 months

Pain measured by the SF-36v2, American Academy of Orthopaedic Surgeons Lower Limb Outcomes Questionnaire, and medication use.

Healing IndexUp to 24 months post-consolidation of the treated limb, an expected total average of 29 months

The total treatment period with the PRECICE System in situ, divided by the length of bone growth in centimeters.

Device-related complicationsUp to 24 months post-consolidation of the treated limb, an expected total average of 29 months

Trial Locations

Locations (6)

Hospital for Special Surgery

🇺🇸

New York, New York, United States

Loma Linda University

🇺🇸

Loma Linda, California, United States

Paley Advanced Limb Lengthening Institute

🇺🇸

West Palm Beach, Florida, United States

Sinai Hospital of Baltimore

🇺🇸

Baltimore, Maryland, United States

Cincinnati Children's Hospital Medical Center

🇺🇸

Cincinnati, Ohio, United States

Nemours Children's Hospital

🇺🇸

Orlando, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath